Treatment with neuroendocrine hormones has been suggested to promote reconstitution of the immune system after hematopoietic stem cell transplantation (HSCT). We investigated the expression of genes encoding receptors for growth hormone (GH), insulin-like growth factor-1 (IGF-1) and triiodothyronine ( 
graft rejection and ablate malignant cells, the patients are subjected to a pre-transplantation conditioning regime prior to HSCT. Because the conditioning results in severe immunosuppression, the patients have an increased susceptibility to infections during reconstitution of the immune system after HSCT. It is, therefore, desirable to shorten and mitigate this period of immunosuppression and impaired immune function, which can last from a few months to several years. Cytokines, such as granulocyte-colony stimulating factor (G-CSF) and granulocyte/monocyte-colony stimulating factor (GM-CSF), are currently used to stimulate reconstitution of the immune system after HSCT.
1,2 G-CSF has been demonstrated to promote hematopoietic recovery, but the treatment does not improve survival rates.
3 Interleukin (IL)-2 has also been given to patients post HSCT to increase immune reconstitution and reduce the relapse rate, but there are conflicting results from different studies. 1 Systemic administration of cytokines is associated with significant toxic effects. 4 Several neuroendocrine hormones, including growth hormone (GH), insulin-like growth factor-1 (IGF-1) and thyroid hormone (triiodothyronine, T 3 ), have been demonstrated to exert stimulatory effects on the immune system. Treatment with neuroendocrine hormones post HSCT has been suggested to be more effective and better tolerated than treatment with cytokines. This is based on the pleiotropic effects of neuroendocrine hormones, and their limited toxicity after systemic administration. 4 The hematopoietic activity of GH and prolactin (PRL) has been studied both in vivo and in vitro. 1 Studies in animal models have shown that these two neuroendocrine hormones are important for hematological activity, but since the models analyzed are deficient in several hormones, the importance of each hormone can not be fully determined. 5, 6 GH has been suggested to have an immunomodulatory effect on development, maintenance and function of the immune system. [7] [8] [9] GH deficiencies in humans do not, however, present as clinically significant hematological deficiencies. GH binds to the GH receptor (GHR) which is a member of the cytokine family of receptors. 10, 11 Flow cytometry has demonstrated the presence of GHR in several human tissues, including peripheral blood mononuclear
Bone Marrow Transplantation cells (PBMC). 12 GHR expression was detected by RT-PCR in human liver, in the human B lymphocyte cell line IM-9 11 and in PBMC. 13 The actions of GH are mediated by IGFs, 14 but IGFs may have direct effects as well. 15, 16 IGFs are potent mitogens for cells in culture. 17 IGF-I is synthesized in the liver. IGF-I receptor (IGF-IR) is a heterotetrameric tyrosine kinase that mediates most of the biologic effects of IGFs. 17 IGF-IR expression has been demonstrated in several tissues including PBMC. 13 Thyroxine (T 4 ) and T 3 are both secreted by the thyroid gland, but T 3 is the biologically active form of the hormone. Lymphocytes, among other cells and tissues, have been demonstrated to convert T 4 into the active T 3 .
18 T 3 affects lymphocyte development and may also affect differentiation of lymphocyte subpopulations. 19 Thyroid hormone acts through nuclear hormone receptors. Four thyroid hormone receptors (THR) have been identified, TR␣1, Tr␣2, TR␤1 and TR␤2, and all but TR␣2 bind T 3 .
20 TR␣1 and TR␤1 have been demonstrated to exert inhibitory effects on the activity of AP-1, an important transcription factor regulating expression of many different genes. AP-1 is involved in regulation of the inflammatory response 21 and stage-specific functions required for B cell proliferation and differentiation. 22 To evaluate the importance of neuroendocrine hormone activity during immune reconstitution after HSCT, we have analyzed the expression of genes encoding receptors for GH, IGF-1 and T 3 , at various time points after HSCT, as well as hormone levels in serum.
Materials and methods

Patients and donors
Sixteen consecutive patients who were treated with HSCT at Huddinge University Hospital were included in the study. Peripheral blood samples were obtained from the patients at various time points early after HSCT and from 15 healthy volunteers (age 23-49 years, 10 females and five males) recruited among the laboratory personnel (ethical permission 329/97 from the Ethical Committee at Huddinge University Hospital, Stockholm, Sweden). Six of the patients received peripheral blood stem cells (PBSC) and 10 patients received bone marrow (BM). The transplantation procedure has been described in detail elsewhere. 23 Patient characteristics are described in Table 1 . To perform a longitudinal study covering early as well as late phases of immune reconstitution, samples were collected at several time points for six of the patients and at a single time point, 1 or 2 months post HSCT, for 10 of the patients (Table 2) . For medical reasons samples could not be obtained at all time points. The conditioning regimen was cyclophosphamide (60 mg/kg/day × 2) and 10 Gy of total body irradiation (TBI), with addition of antithymocyte globulin (ATG) in 10/16 of the patients. Two of the patients were treated with fractionated TBI (3.6 Gy × 4). Busulphan (4 mg/kg/day × 4) and cyclophosphamide without TBI were used as conditioning in two of the cases. 24 Thirteen patients were given methotrexate and cyclosporine A as graft-versus-host disease (GVHD) prophylaxis. 25 In two of the patients methotrexate was replaced by prednisolone. One patient received T cell-depleted stem cells due to HLA-mismatched unrelated graft. The procedure for T cell depletion using antibodies coupled to magnetic beads has been described earlier. 26 Additional details about the transplantation procedure and supportive care have been published elsewhere. 27, 28 
Cell lines
Cell lines IM-9 and MCF-7 served as positive controls in all RT-PCR assays. IM-9, a B cell line expressing the GHR, IGF-IR and THR, [29] [30] [31] was donated by Dr Björk (Pharmacia and Upjohn, Stockholm, Sweden). MCF-7, a human breast cancer cell line expressing the IGF-1 receptor and the thyroid hormone receptor, 32, 33 was donated by Dr Bredin (Division of Clinical Immunology, Huddinge University Hospital, Stockholm, Sweden). Both cell lines were grown in RPMI-1640 supplemented with 20 mm HEPES, 2 mm l-glutamine, 50 IU/ml penicillin, 50 g/ml streptomycin and 10% fetal calf serum (FCS), in 37°C with 5% CO 2 . The cells were harvested and washed once before RNA extraction.
Isolation of mononuclear cells from peripheral blood
PBMCs were separated from peripheral blood by gradient centrifugation on Lymphoprep (Nycomed-Pharma AS, Oslo, Norway). The cells were washed twice in PBS and then frozen in liquid nitrogen in FCS containing 10% DMSO, until RNA extraction was performed.
RNA extraction and cDNA synthesis
Total RNA was extracted using RNAzol B (AMS Biotechnology AB, Stockholm, Sweden), according to the protocol supplied by the manufacturer. The concentration and purity of the preparation was determined by measuring the absorbance at 260 and 280 (UV4 Unicam UV/Vis Spectrometer, ATIUnicam, Cambridge, UK). The integrity of the RNA was confirmed on a 1% agarose gel. If the gel showed DNA contamination, the sample was further purified using the RNA clean-up protocol from the RNeasy kit (Qiagen, Hilden, Germany). The cDNA synthesis was performed using the First-Strand cDNA Synthesis kit (Pharmacia Biotech, Uppsala, Sweden). 1-5 g of the total RNA preparation was diluted in DEPC treated water to a volume of 8 l and denaturated for 10 min at 65°C. The RNA solution was mixed with 5 l Bulk Reaction mix (containing reverse transcriptase, bovine serum albumin (BSA) and dNTPs), 1 l dithiothreitol (DTT), and 1 l random hexadeoxynucleotide primer (pd(N) 6 ). The mixture was incubated for 1 h at 37°C.
PCR and PCR primers
PCR was performed in a total volume of 10 l 1 × PCR buffer (1.5 mm MgCl 2 , 50 mm KCl, 10 mm Tris-HCl pH 8.3, 0.2 mm of dNTPs, 0.5 m of the forward primer and 0.5 m of the reverse primer, 5% glycerol, 0.1 g/l cresol red, 0.03 U/l Taq polymerase (AmpliTaq, Perkin Elmer, Roche Molecular System, Branchburg, USA)) containing 2 l cDNA. The optimal number of cycles was determined empirically. The PCR was performed using a thermal cycler (PTC-200 Peltier Thermal Cycler, MJ Research Inc, CA, USA) and the PCR program for IGF-IR, GHR, and ␤-actin was as follows: preheating at 94°C for 3 min followed by 30 cycles of denaturation at 94°C for 30 s, annealing at 50°C for 1 min, extension at 72°C for 1 min and a final elongation step at 72°C for 10 min. The PCR program for TR␣1 was: preheating at 94°C for 3 min followed by 35 cycles of denaturation at 94°C for 30 s, annealing at 55°C for 1 min, extension at 72°C for 1 min and a final elongation step at 72°C for 10 min. The following PCR primers were used: IGF-1R forward: 5Ј-ACC ATT GAT TCT GTT ACT TC-3Ј, IGF-1R reverse: 5Ј-ATA CTC TGT GAC ATT CTT AA-3Ј, GHR forward: 5Ј-GGA TAA GGA ATA TGA AGT GC-3Ј, GHR reverse: 5Ј-GAT TTC TCA TGG TCA CTG C-3Ј, TR␣-1 forward: 5Ј-CCC CAC ACC CCT TCT CTC CT-3Ј, TR␣-1 reverse: 5Ј-CCG CCC TTC CCC TAC CTT CT-3Ј, ␤-actin forward: 5Ј-GAC TTC GAG CAA GAG ATG G-3Ј, ␤-actin reverse: 5Ј-GCT CAG GAG GAG CAA TGA T-3Ј. The IGF-IR primers, which were based on the cDNA sequence from human IGF-IR, gave a product with 599 base pairs (bp). 34 The GHR primer sequences were located on exons 7 and 10 and produced a PCR product of 453 bp. 11 The TR␣1 primer sequences were located on exons 7 and 8 of the TR␣1 gene and gave a PCR product of 212 bp. 35 The PCR product obtained using the ␤-actin primers was 340 bp.
The PCR products were visualized by electrophoresis in ethidium bromide-stained agarose gels. Quantification of the PCR products was performed by densitometry with a CCD camera system Diana v1.6 (Fuji Film AB, Sweden) and analyzed using the software Tina 2.0. OD quota was calculated by division of the OD for the receptor RNA with the OD for the ␤-actin RNA. The quotas were normalized with the mean of the controls for each receptor, creating a relative value for the RNA expression of the receptors.
Repeating the analysis of a sample four times gave similar results (data not shown).
Serum levels of T 3 , T 4 , TSH and IGF-I
Serum samples, from patients 1, 11 and 12, were collected at several time points, from 1 to 10 months post HSCT. The serum levels of T 3 , T 4 , thyroid stimulating hormone (TSH) and IGF-I were analyzed with standardized analyses at the routine laboratories at Huddinge University Hospital and Karolinska University Hospital.
Statistical analysis
Differences between the mean values for the different time points were compared using the Wilcoxon rank-sum test. Significance was achieved when P Ͻ 0.05. Calculations were performed using the software JMP (SAS Institute Inc., Cary, NC, USA).
Results
Clinical outcome
The clinical data of the patients included in the study are listed in Table 1 . The mean follow-up time was 3 months. Acute GVHD (aGVHD) grade II occurred in two patients and another two patients developed grade III aGVHD. Five patients developed moderate-severe chronic GVHD (cGVHD). Seven of the 16 patients passed away during the follow-up time. Patient 1 developed severe cGVHD affecting the liver, resulting in low levels of IGF-1 at 9 months post HSCT.
RNA expression of neuroendocrine factor receptors in PBMC
The RNA expression for GHR, IGF-IR and TR␣1 was analyzed in PBMC from 16 patients at various time points after HSCT and 15 healthy controls, using semiquantitative RT-PCR with ␤-actin as a reference. Figure 1 demonstrates the expression of IGF-IR and TR␣1 in PBMCs isolated from patient 1, 3 months after HSCT, and from one healthy control. The PCR products representing the respective genes are shown at the expected positions. We could not detect RNA for GHR in any of the samples. The correct PCR product for GHR was, however, demonstrated in the positive controls IM-9 and MCF-7 cell lines.
Expression of IGF-IR and THR at various time points post HSCT
Samples from patients treated with HSCT were collected at various time points post HSCT, as indicated in Table 2 . The expression of each receptor in the different patient samples was related to the mean value of the expression of the corresponding receptor in the controls, as described in Materials and methods. Comparing the relative expression of RNA for IGF-IR and TR␣1 in PBMC from patients and controls revealed an expression profile over time. TR 1 a -actin b Figure 1 Expression of GHR, IGF-IR, TR␣1 and ␤-actin in PBMC. RT-PCR was performed on total RNA from PBMC isolated from a patient 3 months after HSCT, a healthy control, the cell line IM-9 and the cell line MCF-7. The size of the PCR products are 453 bp for GHR, 599 bp for IGF-IR, 212 bp for TR␣1 and 340 bp for ␤-actin. HaeIII-digested pBR322 was used as a molecular weight marker. Figure 2 shows the TR␣1 expression pattern for the patients and controls at all time points, compared to the mean for each time point. There is a peak of RNA expression for TR␣1 at 1.5 months after HSCT where three-fold higher values can be seen compared to the controls (P Ͻ 0.01). After 1.5 months the RNA expression for TR␣1 diminishes, but there is a large variation between individuals. The profile for IGF-IR RNA expression differs from the TR␣1 RNA expression profile in several aspects. Firstly, there is substantial variation among the controls with a 10-fold difference in expression between the highest and lowest value. Secondly, there is a significant decrease in IGF-IR RNA expression post HSCT for the whole sample group compared to the controls. Figure 3 demonstrates IGF-IR expression pattern in all patients and controls at all time points, compared to the mean for each time point. The expression of IGF-IR is generally lower in patients at all time points after HSCT compared to the controls. At 1 month after HSCT the mean value for IGF-IR expression in the patient samples is 50% lower (not significant) comBone Marrow Transplantation pared to the mean value for the controls. In the patient samples at 2 and 3 months post HSCT, there is a significant decrease in expression of IGF-IR compared to the controls (P Ͻ 0.0001 and P = 0.01, respectively). Several patient samples, representing all time points post HSCT, contained no detectable RNA for IGF-IR. This lack of RNA expression for IGF-IR was found in 15 of the total 32 samples from patients collected at all time points after HSCT. RNA expression for IGF-IR was demonstrated in all samples from healthy controls. Figure 4 shows the expression profiles for TR␣1 and IGF-IR for patients 1, 11 and 12. The clinical features of these patients did not differ from the rest of the patients (see Table 1 ). For TR␣1 the profiles of single patients correlate well with the profile of the mean values for RNA expression presented in Figure 2 . All patients have a peak of TR␣1 expression 1.5 months after HSCT and the expression values decrease after that point. The expression of IGF-IR demonstrates a higher degree of variation, but in two of the three patients the IGF-IR expression is lower than the controls at all time points after HSCT. In patient 12 there is no detectable expression for IGF-IR at any time point after HSCT.
Time-course expression patterns in individual patients
Levels of T 3 , T 4 , THS and IGF-1
Sera from patients 1, 11 and 12 were collected at several time points after HSCT and analyzed for T 3 , T 4 , TSH and IGF-1. The results are presented in Table 3 . For these three patients, T 3 , T 4 and TSH remained within the normal range (reference values: T3 Ͻ 7.8 pmol/l, T4 8-20pmol/l, TSH 0.3-5.0 mU/l) throughout the whole follow-up period. The levels of IGF-1 were normal (reference values: 120-320 g/l) at all time points tested for patients 11 and 12. In patient 1, IGF-1 was below the normal range only at 9 months post HSCT (data not shown). At this time the patient suffered from severe cGVHD affecting the liver.
Discussion
In the present study we demonstrate an increased expression of TR␣1 RNA in patients at 1.5 months post HSCT, compared to a group of healthy controls, and a decreased expression of IGF-IR RNA at 2 and 3 months post HSCT. We also demonstrated a profile over time for the expression of TR␣1 with peak values for TR␣1 expression at 1.5 months after HSCT and decreasing levels thereafter. The expression levels and pattern of TR␣1 in patients undergoing bone marrow (BM) transplantation has not been studied previously. However, the levels of thyroid hormone expression after HSCT have been extensively explored, and short-term changes in thyroid metabolism were investigated by Schulte et al. 36 The initial decrease in TSH and T 3 within 2 weeks post HSCT was interpreted as an effect of the HSCT per se. After 4 weeks post HSCT the thyroid hormone parameters had normalized in patients who had an uneventful course. 36 In line with previous studies, we found normal serum levels of T 3 , T 4 and TSH, 1 to 12 months after HSCT. Thyroid function in long-term survivors after HSCT has been studied by several groups. Two recent studies report a low incidence of hypothyroidism after HSCT in patients studied 1-10 years post HSCT. 37, 38 In rats, where high levels of T 3 downregulate TR␣1, measured as mRNA or as receptor density, the ligand-receptor interaction of thyroid hormone receptors was demonstrated. 39 Downregulation of TR␣1 mRNA by T 3 has also been demonstrated in cultured cardiomyocytes. 40 This feedback regulation can not explain our data with increased expression of TR␣1 RNA in combination with normal levels of thyroid hormones early after HSCT.
In this study, increased expression of TR␣1 could be due to upregulation of receptor RNA or proliferation of cells expressing the TR␣1. Preliminary data from our laboratory indicate a somewhat higher expression of TR␣1 RNA in T lymphocytes (data not shown). Since the numbers of both B and T lymphocytes are very low 1-2 months after HSCT we consider it more likely that the increased TR␣1 RNA expression is due to upregulation of the receptor. Increased expression of TR␣1 early after HSCT could indicate a role for TR␣1 in the proliferation and development of the immune system. Snell dwarf (dw/dw) mice are deficient in anterior pituitary hormones, resulting in loss of production of GH, PRL and TSH. These mice show impaired bone 41 Other studies have shown that T 3 stimulates human B cell proliferation and differentiation in vitro. 42, 43 Hastings et al 44 have studied the mRNA expression for different thyroid hormone receptors in various stages of B lymphocyte differentiation. The ratio of TR␣1/TR␣2 mRNA expression was found to vary in a stage-specific manner. The transcription factor AP-1 regulates specific functions required for B cell proliferation and differentiation, 22 and TR␣1 has been reported to interfere with AP-1 activity in a T 3 dependent manner. 21 Taken together, these data suggest an interaction between thyroid hormone receptors and AP-1 in B cell differentiation.
In parallel with the increase in TR␣1 expression we also demonstrate decreased expression of IGF-IR RNA post HSCT. IGF-I is known to increase both B-and T-lymphocyte proliferation, but the mechanism of action is unclear. IGF-I plays an important role in B cell development in the BM by acting as a differentiation factor to potentiate pro-B to pre-B cell maturation 45 and by acting as a B cell proliferation cofactor in synergy with interleukin-7 (IL-7). 46 Using a mouse model, Jardieu et al 47 demonstrated that treatment with IGF-I after TBI and HSCT significantly increased the total number of BM B lineage cells compared to animals that were transplanted without IGF-I treatment. In agreement with previous studies, we have demonstrated normal serum levels of IGF-I 1 to 10 months post HSCT. Kauppila et al 38 have demonstrated normal IGF-I levels, 1-10 years after HSCT. A time-dependent reduction in the number of IGF-IR-positive cells following activation, was demonstrated in human T lymphocytes and the Jurkat T cell line. 48 Reconstitution of the immune system requires expansion of the transplanted cells and activation of the lymphocytes. Our results show decreased expression of IGF-IR RNA that might be associated with activation of the lymphocytes post HSCT.
The euthyroid sick syndrome is associated with decreased levels of T 3 , variable levels of T 4 , and TSH levels Bone Marrow Transplantation that are within the normal range or slightly elevated even though there are no clinical signs of thyroid dysfunction. 49 Thyroid hormone therapy in HIV patients has been shown to increase the CD4 counts and resulted in gain of weight and an increased feeling of well being. 50 Our data do not indicate a direct use of thyroid hormones or IGF-I to promote immune reconstitution, since the serum levels of T 3 , T 4 , TSH and IGF-I are normal throughout the follow-up period. We demonstrate an altered expression of RNA for IGF-IR and TR␣1 which can not be fully explained by anabolic processes in the immune system. An additional possibility to influence the problem of impaired immune function early after HSCT is to minimize the intensity of the conditioning prior to HSCT. Recently, a new nonmyeloablative method for HSCT has been developed, 51 but the effects on immune function post HSCT remain to be elucidated.
